NASDAQ:BCRX
BioCryst Pharmaceuticals Stock News
$4.48
-0.0900 (-1.97%)
At Close: May 02, 2024
BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
09:47am, Monday, 11'th Apr 2022
BCX9930 is a BioCryst Pharmaceuticals' (BCRX) oral Factor D inhibitor being evaluated in several studies for the treatment of complement-mediated diseases
Why BioCryst Pharmaceuticals Stock Is Falling
09:30am, Monday, 11'th Apr 2022
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target. BofA Securities analyst Tazee
BioCryst to Present at Upcoming Investor Conference
08:30am, Monday, 11'th Apr 2022
RESEARCH TRIANGLE PARK, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21st Annual Needham Virtual Healthc
Why BioCryst Pharmaceuticals Stock Is Crashing Today
03:15pm, Friday, 08'th Apr 2022 The Motley Fool
The company is pausing patient enrollment in three clinical studies.
BioCryst Pauses Enrollment in BCX9930 Clinical Trials
01:15pm, Friday, 08'th Apr 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has paused enrollment in clinical trials with BCX9930
Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder
12:27pm, Friday, 08'th Apr 2022
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients. The Company wil
Why BioCryst Pharmaceuticals Stock Is Plunging Today
10:03am, Friday, 08'th Apr 2022
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading significantly lower Friday after the company paused enrollment in clinical trials with BCX9930 while it investigates elevated serum cre
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:15am, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors gra
BioCryst executive sells 20K company shares in first insider selling since May 2021
11:50am, Thursday, 10'th Mar 2022 Seeking Alpha
The shares of commercial-stage biotech, BioCryst Pharmaceuticals (BCRX) are trading lower Thursday after its Chief Discovery Officer Babu Yarlagadda disclosed the sale of 20,000…
BioCryst to Present at Upcoming Investor Conferences
12:00pm, Thursday, 03'rd Mar 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 42nd Annual Health Care Con
BioCryst to Present at Upcoming Investor Conferences
12:00pm, Thursday, 03'rd Mar 2022 GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 9:50 a.m. ET. The event will be held virtually.
BioCryst Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
02:22pm, Friday, 25'th Feb 2022 Seeking AlphaBioCryst''s Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates
05:17pm, Thursday, 24'th Feb 2022 Benzinga
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX ) announced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE). The results showed sustained reductions in attack rates and improved quality of life (QoL) among patients living with HAE, regardless of their baseline attack rates and initial responses to … Full story available on Benzinga.com
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) today announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) showing sustained reductions in attack rates and improvement in quality of life (QoL) among patients living with HAE, regardless of their baseline attack rates and initial responses to ORLADEYO. The data are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held live in Phoenix, Arizona, and virtually, from February 25-28, 2022. "The long-term data from APeX-2 show that HAE patients in our clinical program had an experience consistent with what we are seeing commercially in the real world; that ORLADEYO provides noteworthy, sustained, consistent reductions in HAE attack rates that persist and maintain over time, resulting in meaningful quality of life improvements," said Dr.
Why BioCryst Pharmaceuticals Stock Slid Today
11:30pm, Wednesday, 23'rd Feb 2022 The Motley Fool
The biotech's immediate future doesn't look profitable.